Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes. Journal Abstract

Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.

Publication Date: 2024 Dec 05

Full Text Sources

Authors

Helen Tesfaye; Julie M Paik; Miin Roh; Phyo T Htoo; Heidi Zakoul; Niklas Schmedt; Lisette Koeneman; Deborah J Wexler; Elisabetta Patorno

Abstract

OBJECTIVE

Empagliflozin might lower the risk of diabetic retinopathy (DR) by preventing retinal pericyte loss. However, the role of empagliflozin with respect to DR in patients with type 2 diabetes (T2D) remains unclear.

Source

JAMA ophthalmology

Pub Types(s)

Journal Article

Language

English

PubMed ID

39636645